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of community physicians management of HCV infection.
Responses were obtained from six hepatologists, six intensivists
and six oncologists from various centers in Brazil with experi-
ence of treating HCVI. RESULTS: The expected annual costs per
each disease stage, not treated with antiviral medication, per
patient were: R$1.069 for mild chronic hepatitis, R$1,277.00
for moderate chronic hepatitis, R$1,522.00 for compensated 
cirrhosis, R$15,932.00 for ascites, R$31,352.00 for refractory
ascites, R$21,427.00 for variceal hemorrhage, R$106,922.00 for
hepatic encephalopathy, R$20,884.00 for hepatocellular carci-
noma, R$136,900.00 for liver transplantation, R$10,540.00
liver transplantation after the ﬁrst year and R$789.00 for remis-
sion. CONCLUSIONS: These cost data can be used to model
disease burden in Brazil. The costs increase dramatically in the
more advanced disease health states. Probably, slowing the pro-
gression to these disease states may be cost saving. One USD =
2.57 Brazilian Reais at the moment of the study.
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OBJECTIVES: GERD is one of the most common gastrointesti-
nal disorders. Knowledge on epidemiologic data, treatment
guidelines and patterns and economic details is limited.
METHODS: Extensive desktop research was conducted for
North America, Western and Eastern Europe and Australia using
MEDLINE, EMBASE and Cochrane databases (1995–2004),
telephone interviews, Internet searches (2000–2004). For struc-
tured search all MESH terms applying to GERD, epidemiologic
data, treatment patterns, costs and related issues (22 in total)
were used. RESULTS: Extensive review of obtained literature
revealed 162 articles and other sources of information (websites,
telephone contacts) for further evaluation. Prevalence of weekly
GERD symptoms ranges from 4% (Canada) to 20% (USA). 
Population-based prevalence data are lacking for Austria,
Germany and Eastern European countries. General recommen-
dations for management of GERD consist of symptom-oriented
measures with lifestyle changes and administration of antacids,
Proton-Pump-Inhibitors (PPI) or H2-Receptor-Antagonists. Spe-
ciﬁc guidelines with recommendations on drug treatment exist
in all countries except most of Eastern Europe. Treatment pat-
terns widely follow guidelines with variations in drug dosage and
administration period. Peer-reviewed literature revealed 20 
cost-of-illness studies (16 USA, 1 Canada, 3 Western Europe, 0
Eastern Europe and Australia). In North America total direct
cost (TDC) ranged from €360–€800/a (Canada €700/a). Western
European cost-of-illness studies exist only for Sweden (TDC
€930/a) and Italy (TDC €300/a). From third party payers’ 
perspective main cost drivers are medication (about 40%) and
outpatient care (about 60%). CONCLUSIONS: Although preva-
lence of GERD is high, only few studies focus on its economic
burden, most of them conducted in the USA. Treatment guide-
lines show comparatively uniform features in all investigated
countries, especially concerning the recommendation of PPI
usage. Treatment patterns show wide usage of PPI, except in
Eastern Europe where treatment patterns assumably resemble
those in Western Europe, probably with limitations due to the
countries’ health care systems’ possibilities.
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Artiﬁcial liver support systems (ALS) are a new therapeutic
approach for patients with acute liver failure (ALF) or acute-on-
chronic liver failure (ACLF). Using this technology patients
should have a better chance for regaining their own liver func-
tion or for successful bridging to transplantation. Treatment
costs in Germany are €10–15,000 per patient. OBJECTIVES: To
determine and summarize the scientiﬁc evidence on medical efﬁ-
cacy and economic effectiveness of the use of ALS in patients
with ALF or ACLF. METHODS: In an extensive systematic lit-
erature search in all relevant medical and economic data bases
all published studies on ALS were identiﬁed and systematically
described. All results concerning the treatment of ALF or ACLF
were extracted and if possible synthesized to ﬁnal recommenda-
tions. RESULTS: Three different artiﬁcial liver support systems
could be identiﬁed. For Biologic-DT® neither of the identiﬁed
studies reported medical or economic beneﬁts. For Prometheus®
no randomized controlled studies reporting medical or economic
effects are available. For MARS (Molecular adsorbing recircu-
lating system) for patients with ACLF a signiﬁcant improvement
of clinical parameter and 30d-survival could be demonstrated.
First health economic studies with short time horizon report
costs per QALY of €60,000 and conclude that prolonging the
time horizon would improve cost-effectiveness. All studies show
methodological limitations. CONCLUSION: The present scien-
tiﬁc evidence according to published trials on ALS does not show
any medical or economic beneﬁt of the liver support systems 
BioLogic-DT® and Prometheus®. The limited evidence for the
beneﬁt of the system MARS gives hints that ACLF patients might
clinically beneﬁt and that cost-effectiveness is acceptable. Future
randomized controlled studies with large sample size and health
economic models to estimate long term beneﬁts are necessary to
conﬁrm these results.
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OBJECTIVES: The evidence base for cost-effectiveness analyses
(CEA) often consists of a series of randomised controlled trials
making pair-wise comparisons between several alternative treat-
ments (A vs. B, A vs. C, B vs. D, etc). Furthermore, each trial
may report results at one or more, different, follow-up times. In
order to obtain unbiased estimates of treatment efﬁcacy, and to
produce an appropriate uncertainty analysis in the context of a
CEA, any synthesis of the evidence must ensure that the uncer-
tainty structure arising from the pattern of randomisation is cor-
rectly captured and propagated. METHODS: We studied a set
of 41 randomised trials looking at the healing rates of six treat-
ments for gastro-oesophageal reﬂux disease (GORD). Each trial
reported the healing rate at one or more (average 1.8) follow-up
times at 4, 6, 8, or 12 weeks. There are a possible 15 pair-wise
comparisons between 6 treatments, but, overall, the dataset pro-
vides direct information on only 9 of these, 5 at 4 weeks, 4 at
6, 8 at 8 and 6 at 12. We developed a series of hierarchical
models that “borrow strength” across the incomplete network
of treatment comparisons and also across time points. RESULTS:
We propose an approach that distinguishes between the model
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for the trial baseline, and the model for the relative treatment
effects which the trials were designed to estimate. Methods for
selecting models on the basis of goodness of ﬁt are suggested.
CONCLUSIONS: The models are implemented in the Bayesian
Markov chain Monte Carlo WinBUGS package, so that para-
meter estimation and decision modeling can be integrated into a
single process.
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OBJECTIVES: To assess the cost per symptom occurrence of
GERD management in primary care of naïve and relapser
patients in Campania, a region of southern Italy. METHODS:
Prospective cost of GERD management has been calculated in
patients who consulted 259 general practitioners (GPs). Direct
costs to the National Health Service (tariffs 2005) including
drugs, physicians’ visits and diagnostic tests were calculated and
expressed in Euro. Mann-Withney test was used where indicated.
To investigate the association between cost and its potential
determinants (age, sex, disease severity and clinical approach—
therapeutic/ empirical or diagnostic) bootstrap analysis was
used. Data are expressed as mean ± SEM. Societal perspective
was adopted. RESULTS: We studied 1343 patients with GERD,
456 naïve (48% males; mean and age range: 49.4y, 18–89) and
887 relapser (51%; 55.2, 18–98). Overlapped dyspeptic symp-
toms were found in 75.2% and 73.1% of naïve and relapser
patients respectively. Therapeutic approach was preferred by GPs
in both groups (naïve 55.9%; relapser 72.8%). The cost of
GERD management was signiﬁcantly different between naïve
and relapser groups (€90.4 ± 4.04 vs. 122.1 ± 4.15; p < 0.0001).
This difference was partially attributable to prescribed drugs
(€47.6 ± 2.85 vs. €83.4 ± 3.47; p < 0.0001). Proton pump
inhibitors were the most prescribed drugs by GPs (naïve 62.5%;
relapser 67.5%). Age, male sex, disease severity and diagnostic
approach were signiﬁcantly (p < 0.05) associated with cost
increase in both groups. CONCLUSIONS: In primary care
second or following approach of GERD patient is more costly
respect to that of naive. Disease severity and diagnostic approach
increase the cost of GERD management independently to time
approach.
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OBJECTIVES: Reimbursement authorities are faced with 
decision-making for numerous launches of biotechnology/
pharmaceutical technologies with uncertain “value-for-money”.
Concurrently, biotechnology/pharmaceutical companies are
assessing their developmental pipeline. An economic modeling
application, based on cost-effective methodology, is illustrated
which helps the manufacturer analyze and predict cost-effective
patient populations, market access value, and pricing for future
product opportunities by considering payers’ willingness-to-
pay thresholds (WTPT). METHODS: A deterministic Markov
Excel® model was developed comparing chronic liver disease
populations treated with a new product, Drug X, to established
standard care. The US, Italy, UK, and German health care system
perspectives were evaluated; methods followed respective
country economic guidelines. Literature review provided disease
transitions, utilities, resource utilization and direct cost esti-
mates. Physicians validated disease progression rates, treat-
ment patterns and resource utilization. Quality-adjusted life
expectancy, total lifetime costs and incremental cost-utility ratios
between strategies were estimated. A uniﬁed analysis assessed the
weighted incremental cost-utility outcomes and trade-offs for
sub-population scenarios. Crystal Ball® software predicted drug
price ranges for various scenarios at ﬁxed payer’s WTPT. Prob-
abilistic stochastic Monte Carlo sensitivity analysis was con-
ducted for all input parameters. RESULTS: The model estimated
that the most cost-effective sub-populations included the F3 and
F4 Metavir patients, compared to the broadest population. At a
payer’s WTPT of $50,000/QALY, the incremental drug efﬁcacy
required in F3 and F4 to be cost-effective over 20 years was pre-
dicted at 14% and 43.5%, for annual price ranges of US$1500
and US$4000, respectively. Sensitivity analysis determined the
critical drivers: incremental drug efﬁcacy/safety rates, price,
patient sub-population and utility values. CONCLUSION: Eco-
nomic valuation modeling has been inﬂuential in providing guid-
ance on payer market access dynamics; predicting cost-effective
positioning and treatment populations; and projecting pricing
for new product opportunities. Increasingly, manufacturers’ rec-
ognize that this approach may reduce product development risk
by establishing more realistic estimates of market potential,
pricing and societal need.
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OBJECTIVES: Irritable bowel syndrome (IBS) is a prevalent
functional gastrointestinal dysmotility disorder. This study aimed
to estimate the burden of illness of a Dutch population of 
community dwelling patients suffering from IBS. METHODS:
Patients identiﬁed at community pharmacies, using mebeverine
as a proxy for IBS, were administered a questionnaire regarding
1) the Rome II criteria for IBS, 2) predominant type of stool
during complaints, 3) severity of symptoms (abdominal pain and
discomfort), 4) generic and disease-speciﬁc quality of life, 5)
current health status (utilities), and 6) loss of productivity.
RESULTS: A total of 375 users of mebeverine were identiﬁed of
which 169 patients met the Rome II criteria for IBS, and were
included in the study. More than half (58%) of the IBS patients
reported severe abdominal pain and complaints. Generic and
disease-speciﬁc quality of life outcomes showed impairment on
all dimensions. The current health status perceived by IBS
patients was 62% (95%CI: 60–66) of full health. Transformed
to population utilities, health status was 0.67 (95%CI:
0.65–0.68). The loss in productivity of IBS patients was 1.8 days
(95%CI: 1.1–2.5) per month. CONCLUSIONS: This study con-
ﬁrmed that the burden of illness of IBS in The Netherlands is
substantial. IBS patients treated with mebeverine experienced
low quality of life and suffered from severe pain. Based on these
results, more attention for the diagnosis and treatment of IBS
seems to be justiﬁed.
